Product nameAnti-FOXO1A antibody - ChIP Grade
See all FOXO1A primary antibodies
DescriptionRabbit polyclonal to FOXO1A - ChIP Grade
Specificityab39670 detects endogenous levels of total FOXO1A.
Tested applicationsSuitable for: ICC/IF, WB, IHC-P, ELISA, ChIPmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide corresponding to Human FOXO1A. Synthetic non-phosphopeptide derived from human FOXO1A around the phosphorylation site of serine 319.
Database link: Q12778
- WB: HeLa and 293 cell extracts. IHC-P: human breast carcinoma tissue. ICC/IF: MCF7 cells.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS
Without Mg2+ and Ca2+
Concentration information loading...
PurityImmunogen affinity purified
- Signal Transduction
- Signaling Pathway
- Nuclear Signaling
- Nuclear Hormone Receptors
- Epigenetics and Nuclear Signaling
- Nuclear Signaling Pathways
- Nuclear Receptors
ChIP Related Products
Corresponding phospho antibody
Our Abpromise guarantee covers the use of ab39670 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 1 - 5 µg/ml.|
|WB||1/500 - 1/1000. Detects a band of approximately 70 kDa (predicted molecular weight: 70 kDa).|
|IHC-P||Use at an assay dependent concentration.|
|ChIP||Use at an assay dependent concentration. PubMed: 20467422See Abreview.|
FunctionTranscription factor which acts as a regulator of cell responses to oxidative stress. In the presence of KIRT1, mediates down-regulation of cyclin D1 and up-regulation of CDKN1B levels which are required for cell transition from proliferative growth to quiescence.
Involvement in diseaseDefects in FOXO1 are a cause of rhabdomyosarcoma type 2 (RMS2) [MIM:268220]. It is a form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchimal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas. Note=Chromosomal aberrations involving FOXO1 are found in rhabdomyosarcoma. Translocation (2;13)(q35;q14) with PAX3; translocation t(1;13)(p36;q14) with PAX7. The resulting protein is a transcriptional activator.
Sequence similaritiesContains 1 fork-head DNA-binding domain.
modificationsPhosphorylated by AKT1; insulin-induced (By similarity). IGF1 rapidly induces phosphorylation of Ser-256, Thr-24, and Ser-319. Phosphorylation of Ser-256 decreases DNA-binding activity and promotes the phosphorylation of Thr-24, and Ser-319, permitting phosphorylation of Ser-322 and Ser-325, probably by CK1, leading to nuclear exclusion and loss of function. Phosphorylation of Ser-329 is independent of IGF1 and leads to reduced function. Phosphorylated upon DNA damage, probably by ATM or ATR.
Cellular localizationCytoplasm. Nucleus. Shuttles between cytoplasm and nucleus.
- Information by UniProt
- FKH 1 antibody
- FKH1 antibody
- FKHR antibody
Lanes 1-3 : Anti-FOXO1A antibody - ChIP Grade (ab39670) at 1/500 dilution
Lanes 4-5 : Anti-FOXO1A (phospho S319) antibody (ab38516) at 1/500 dilution
Lane 1 : 293 Cell extract
Lanes 2-5 : HeLa Cell extract
Lysates/proteins at 30 µg per lane.
All lanes : Alkaline Phosphatase AffiniPure Goat Anti-Rabbit IgG (H+L)
Predicted band size: 70 kDa
Observed band size: 70 kDa
Running conditions: 60v, 30min; 120v 60min
Transfer conditions: 150mA 120min Nitrocellulose membrane.
Blocking conditions: 5% non-fat milk in TBST, RT, 90min.
Primary antibody incubation: 4?, overnight.
Washing condition: 5 ml TBST, 4 x 5min.
Tissue microarray analysis of FOXO1 expression
Representative images of FOXO1 expression in normal brain tissue (C, ×200); grade II diffuse astrocytoma (D, ×200); grade III anaplastic astrocytoma (E, ×200) and grade IV glioblastoma (F, ×200).
FOXO1 was detected using ab39670 at 1/200 dilution. The tissue microarray was contructed from paraffin-embedded human brain tissue samples.
(After Figure 1 of Chen et al).
Paraffin-embedded human brain tissue stained for FOXO1 with ab39670 at 1/50 dilution in immunohistochemical analysis. The right hand image was obtained following blocking with the immunizing peptide.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ab39670. (Left image: without peptide; Right image: with peptide 1µg/ml).
ICC/IF image of ab39670 stained MCF7 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab39670, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Anti-FOXO1A antibody - ChIP Grade (ab39670) at 1/1000 dilution + Whole cell lysates prepared from human Jurkat cells at 200000 cells
HRP-conjugated donkey polyclonal to rabbit IgG at 1/2000 dilution
Developed using the ECL technique.
Predicted band size: 70 kDa
Observed band size: 70 kDa
Additional bands at: 45 kDa (possible non-specific binding), 50 kDa (possible non-specific binding), 80 kDa (possible non-specific binding)
Exposure time: 30 seconds
Primary diluted in PBS (BSA + 0.1% Tween20) and incubated with sample for 90 minutes at 20°C.
This product has been referenced in:
- Hemmer MC et al. E47 modulates hepatic glucocorticoid action. Nat Commun 10:306 (2019). Read more (PubMed: 30659202) »
- Park MK et al. PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. Nat Commun 10:636 (2019). Read more (PubMed: 30733438) »